| Newslatter
  Monthly E-newsletter - December 2017
Pharma Affairs Newsletter
Pharma Advancment news letter subscribe Subscribe
December , 2017 > >Pharma Affairs e-Newsletter
FDA Moves Signal Storm Warning For Pharma
DNEW YORK,(Reuters Breaking views) - New commissioner Scott Gottlieb is wasting no time combating high prices. The U.S. agency will expedite reviews of generic-drug applications to promote competition. The changes will batter the likes of Valeant and Cardinal Health, and cast a cloud over branded drug makers. .
Takeda Pharma, Biological E In Pact For Vaccine Development
Takeda Pharmaceutical Company and Biological E Ltd (BE) have signed two licensing agreements for development and delivery of affordable combination vaccines for low and middle-income countries
Inovio Signs Collaborative Research Agreements
Inovio Signs Collaborative Research Agreements With Wistar Institute for DNA-based Immunotherapies and Vaccines New Agreement Follows Dr. David B. Weiner's Move to Wistar from the University of Pennsylvania (UPenn)
Kyowa Hakko Kirin Announces Positive Results Of The Phase 3 Clinical Study Of Mogamulizumab (KW-0761)
Kyowa Hakko Kirin Co., Ltd. announced the Global Phase 3 study (MAVORIC: Mogamulizumab anti-CCR4 Antibody Versus ComparatOR In CTCL) investigating the use of mogamulizumab (KW-0761) in patients with cutaneous T-cell lymphoma (CTCL) met its primary endpoint of progression free survival.
Advertise in Our Next Issue - Contact





If you do not wish to receive any more Continuum of Pharma Affairs, you may {unsubscribe}Unsubscribe{/unsubscribe} here.

Contact the following departments for more information:
Untitled Document